Mainz Biomed BV (MYNZ)vsNatera Inc (NTRA)
MYNZ
Mainz Biomed BV
$1.43
-2.72%
HEALTHCARE · Cap: $7.90M
NTRA
Natera Inc
$311.69
-0.79%
HEALTHCARE · Cap: $44.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 410100% more annual revenue ($2.71B vs $659,940). MYNZ leads profitability with a 0.0% profit margin vs -7.1%. NTRA earns a higher WallStSmart Score of 31/100 (F).
MYNZ
Avoid18
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 37.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
0.0% earnings growth
Weak financial health signals
Trading at 25.1x book value
ROE of -10.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MYNZ
The strongest argument for MYNZ centers on Price/Book.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : MYNZ
The primary concerns for MYNZ are EPS Growth, Market Cap, Profit Margin.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
MYNZ profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.51 — expect wider price swings.
NTRA is growing revenue faster at 37.7% — sustainability is the question.
MYNZ generates stronger free cash flow (-7M), providing more financial flexibility.
Bottom Line
NTRA scores higher overall (31/100 vs 18/100) and 37.7% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mainz Biomed BV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Mainz Biomed BV is an innovative biotechnology company specializing in the development of advanced diagnostic solutions for early cancer detection, with a particular emphasis on gastrointestinal disorders. The company's flagship product, a proprietary non-invasive colorectal cancer screening test, employs state-of-the-art biomarker technology to improve the accuracy and accessibility of screenings. As a key player in the rapidly expanding diagnostics market, Mainz Biomed is dedicated to meeting critical clinical needs and enhancing patient outcomes. With a strong intellectual property position and a focus on research and development, the company is poised to capitalize on the increasing global demand for effective cancer diagnostic tools.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?